BIASIOLO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 4028
EU - Europa 530
AS - Asia 441
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5002
Nazione #
US - Stati Uniti d'America 4025
CN - Cina 376
SE - Svezia 125
FI - Finlandia 113
IT - Italia 85
DE - Germania 79
UA - Ucraina 62
VN - Vietnam 54
GB - Regno Unito 40
IE - Irlanda 13
IN - India 11
NL - Olanda 4
BG - Bulgaria 3
CA - Canada 3
ES - Italia 2
FR - Francia 2
AU - Australia 1
EU - Europa 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RO - Romania 1
Totale 5002
Città #
Fairfield 650
Chandler 492
Woodbridge 368
Jacksonville 354
Wilmington 301
Houston 286
Ashburn 268
Cambridge 265
Seattle 225
Ann Arbor 186
Princeton 132
Beijing 73
San Diego 73
Nanjing 72
Des Moines 64
Medford 58
Dong Ket 54
Padova 54
Roxbury 48
Boardman 46
Dearborn 44
Helsinki 41
Guangzhou 33
Shenyang 28
Falls Church 20
Jinan 19
Hebei 18
Nanchang 18
Changsha 17
Hefei 14
Dublin 13
Kunming 12
Jiaxing 9
Norwalk 9
Detroit 7
Tianjin 7
Redwood City 6
Zhengzhou 5
Haikou 4
Indiana 4
Kharkiv 4
Ningbo 4
Phoenix 4
Wuhan 4
Baotou 3
Bologna 3
Chengdu 3
Chicago 3
Fuzhou 3
Lanzhou 3
London 3
Rockville 3
Shanghai 3
Sofia 3
Venezia 3
Auburn Hills 2
Borås 2
Campodarsego 2
Gubbio 2
Mestre 2
Paris 2
Quzhou 2
Redmond 2
Shaoxing 2
Simi Valley 2
Amsterdam 1
Arezzo 1
Changchun 1
Groningen 1
Guiyang 1
Hangzhou 1
Harbin 1
Horia 1
Huzhou 1
L'aquila 1
Lachine 1
Las Vegas 1
Leawood 1
Lebanon 1
Melbourne 1
Minneapolis 1
Munich 1
Nagold 1
Orange 1
Pavia 1
Pinehaven 1
Piove Di Sacco 1
Polska 1
Taiyuan 1
Toronto 1
Treviso 1
Verona 1
Weimar 1
Xian 1
Totale 4495
Nome #
Binding and Uptake into Human Hepatocellular Carcinoma Cells of Peptide-Functionalized Gold Nanoparticles 164
PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting 158
SCCA1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity 129
SQUAMOUS CELL CARCINOMA ANTIGEN- IMMUNOGLOBULIN M (SCCA-IGM) AS BIOMARKER IN LIVER DISEASE: BIOLOGICAL ASPECTS AND CLINICAL APPLICATIONS 104
A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses 103
Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome 99
SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity 97
[Anti-β2 Glycoprotein I - β2 Glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases 95
PURIFICATION OF ANTICARDIOLIPIN AND LUPUS ANTICOAGULANT ACTIVITIES BY USING CARDIOLIPIN IMMOBILIZED ON AGAROSE BEADS 94
Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma 94
Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. 93
ANTIPHOSPHOLIPID ANTIBODIES ARE NOT PRESENT IN THE MEMBRANE OF GEL-FILTERED PLATELETS OF PATIENTS WITH IGG ANTICARDIOLIPIN ANTIBODIES, LUPUS ANTICOAGULANT AND THROMBOSIS 92
BINDING OF AUTOIMMUNE CARDIOLIPIN-REACTIVE ANTIBODIES TO HEPARIN - A MECHANISM OF THROMBOSIS 92
Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma 86
A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants 84
Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. 81
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 81
Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface 80
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. 80
Exogenous Administration of SERPINB3 Inhibits Cell Reprogramming 80
The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. 80
Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis 80
Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis 80
A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation 77
Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study 75
A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment 70
SerpinB3 promotes pro-fibrogenic responses in activated hepatic stellate cells 70
A comparison of lupus anticoagulant-positive patients with clinical picture of Antiphospholipid syndrome and those without 67
REVERSAL OF EXCESSIVE EFFECT OF REGULAR ANTICOAGULATION - LOW ORAL DOSE OF PHYTONADIONE (VITAMIN-K1) COMPARED WITH WARFARIN DISCONTINUATION 66
COMBINING SCCA-IGM AND AFP-IGM LEVELS INCREASES ACCURACY OF HEPATOCELLULAR CARCINOMA DETECTION 66
SERPINB3 delays glomerulonephritis and attenuates the lupus-like disease in lupus murine models by inducing a more tolerogenic immune phenotype 66
Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden) 65
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 65
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 64
Serpinb3 is overexpressed in the liver in presence of iron overload 63
Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity 60
HEPATIC PROGENITOR CELLS OVEREXPRESS SERPINB3 IN A MOUSE MODEL OF FULMINANT HEPATITIS 60
Low intensity warfarin therapy. 59
Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis 58
CIRCULATING SURVIVIN-IGM IS A NOVEL CANDIDATE BIOMARKER OF CIRRHOSIS AND INCREASES WITH CHILD SCORE IN PATIENTS AFFECTED BY LIVER DISEASES 56
EVALUATION OF THE ANALYTICAL SPECIFICITY OF SCCA-IGM ASSAY FOR MONITORING PATIENTS WITH CIRRHOSIS 56
Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers 56
SERPINB3 modulates TGF-beta expression in chronic liver disease. 55
SCCA1-IGM AND SCCA2-IGM COMPARED WITH TOTAL SCCA-IGM FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA 55
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic anticoagulant therapy: a prospective multicenter study 54
Effect of anti-beta-2-glycoprotein I Lupus Anticoagulants on fibrin polymerization and fibrinolysis 53
Initiation of warfarin treatment in outpatients with nonrheumatic atrial fibrillation: a scheme for early prediction of maintenance dose 51
HPYPOXYA UP-REGULATES SERPINB3 IN HEPATIC CANCER CELLS: A HIF-2a ASSOCIATED EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION 49
SQUAMOUS CELL CARCINOMA ANTIGEN (SCCA) ENHANCES LIVER REGENERATION AFTER PARTIAL HEPATECTOMY 49
HYPOXIA UP-REGULATES SERPINB3 IN HEPG2 CELLS: A REDOX SENSITIVE EVENT RELATED TOEPITHELIAL TO MESENCHYMAL TRANSITIONAND INVASIVENESS 48
Anti phospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purifled IgG with anticardiolipin and anti-beta 2-glycoprotein I activity 47
RUOLO DI SERPINB3 ELLA PROGRESSIONE DELLA MALATTIA EPATICA 47
Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients 46
HEPATOCELLULAR CARCINOMA INDUCES SPECIFIC IGM-BIOMARKERS IMMUNE COMPLEXES 45
Autoimmune antiphospholipid antibodies: What is their true target? 44
The risk of overdiagnosis of antiphospholipid syndrome 43
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothombin time monitor (Coagucheck) 41
CHARACTERIZATION OF SCCA-1(SERPINB3) ISOFORMS IN HEPATOCELLULAR CARCINOMA 41
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 41
CARATTERIZZAZIONE BIOLOGICA E FUNZIONE DELLA NUOVA ISOFORMA SCCA-PD 40
SEX DEPENDENT IL-6 DEREGULATION BY SERPINB3 IN A TRANSGENIC MOUSE MODEL 39
OSTEOPONTIN-IGM IN THE DIAGNOSIS OF HCC 39
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 38
LRP-1 BINDS SERPINB3 AND MEDIATES ITS MIGRATORY ACTIVITY 38
OVEREXPRESSION OF SERPINB3 IN HEPATIC PROGENITOR CELLS IN A MOUSE MODEL OF ACUTE LIVER INJURY 35
Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma 35
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 32
MATRIX METALLOPROTEINASE 9 (MMP9)-IgM COMPLEX: AN EMERGING NOVEL BIOMARKER IN COLORECTAL CANCER 31
CELLULE PROGENITRICI EPATICHE ESPRIMONO SERPINB3 IN UN MODELLO MURINO DI EPATITE FULMINANTE 31
DETERMINAZIONE DELL’IMMUNOCOMPLESSO VEGF-IgM NELL’ EPATOCARCINOMA 30
Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. 30
Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA) 30
SERPINB3 AND TGF-BETA1 CORRELATION IN CHRONIC LIVER DISEASE OF VIRAL ETIOLOGY 29
SERPINB3 AND TGF-BETA IN CHRONIC LIVER DISEASE 28
Anti-beta2-glycoprotein I/beta2-glycoprotein I immune complex in patients with antiphospholipid syndrome and other autoimmune diseases 27
VASCULAR ENDOTELIAL GROWTH FACTOR (VEGF)- IgM COMPLEX FOR THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA 27
SQUAMOUS CELL CARCINOMA ANTIGEN (SCCA)-IgM COMPLEX: SCCA1-IgM and SCCA2-IgM COMPARED TO TOTAL SCCA-IgM FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA 26
ESPRESSIONE DI TGF-b1 NELLA MALATTIA EPATICA EVOLUTIVA 26
SERUM SQUAMOUS CELL CARCINOMA ANTIGEN-IgM (SCCA-IgM) IMMUNOCOMPLEX: A NEW BIOMARKER FOR CANCER OF THE ESOPHAGUS 24
MODULAZIONE DEI LIVELLI DI IL-6 NELLA RIGENERAZIONE EPATICA DA PARTE DI SERPINB3 ED ESTROGENI. ANALISI IN UN MODELLO DI TOPO TRANSGENICO 23
SERPINB3 UP-REGULATION BY HYPOXIA IN HEPG2 CELLS : A HIF-2ALPHA AND REDOX SENSITIVE EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION 22
SERPINB3 AND TGF-BETA1 CORRELATION IN CHRONIC LIVER DISEASE 22
COMPORTAMENTO DI SCCA-IgM NEL SIERO DI BAMBINI HBeAg POSITIVI SEGUITI NEL TEMPO 20
COMBINATION OF BIOMARKERS-IGM BYLOGISTIC REGRESSION IMPROVES DIAGNOSTIC ACCURACY IN HEPATOCELLULAR CARCINOMA 20
SCCA-IgM A MARKER OF HEPATCELLULAR CARCINOMA (HCC) IN PATIENTS WITH CIRRHOSIS 13
SERPINB3 AS A PRO-INFLAMMATORY MEDIATOR IN THE PROGRESSION OF EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE. 8
Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis 7
Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma 5
Semisolid Wet Sol–Gel Silica/Hydroxypropyl Methyl Cellulose Formulation for Slow Release of Serpin B3 Promotes Wound Healing In Vivo 5
Totale 5034
Categoria #
all - tutte 8721
article - articoli 7548
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 151
Totale 16420


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201889 0000 00 014 57576
2018/2019610 201017 36 1071 986158157
2019/20201369 1714719137 120115 201155 1251546362
2020/2021911 40462174 2078 1666 146163114127
2021/2022940 181328476 5368 4780 5515101211
2022/2023770 20310658101 146138 612 0000
Totale 5034